Non-small Cell Lung Cancer Treatment Market Size Share Trends Forecast 2026

Page 1

NON-SMALL CELL LUNG CANCER MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027

© Coherent market Insights. All Rights Reserved


REPORT DESCRIPTION Non-small Cell Lung Cancer Treatment Market - Overview Global Non-small Cell Lung Cancer Treatment Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza), and Ramucirumab (Cyramza)), and Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Others)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was estimated to be valued at US$ 19,161.7 million in 2019, and is expected to exhibit a CAGR of 9.3% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights. Increasing product launches of biosimilars of Bevacizumab is expected to drive growth of the Non-small cell lung cancer treatment market over the forecast period. For instance, in July 2019, Amgen and Allergan plc collaborated and launched MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) in combination with chemotherapy for Non-small cell lung cancer. Furthermore, in 2018, F. Hoffmann-La Roche AG launched atezolizumab under the brand name Tecentriq for the treatment of Non-small cell lung cancer (NSCLC) in India. Moreover, in 2019 Sandoz, a subsidiary of Novartis AG, launched generic oncology medicine, gefitinib, indicated for adult patients with metastatic non-small cell lung cancer. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/nonsmall-cell-lung-cancer-market-241 © Coherent market Insights. All Rights Reserved


REPORT DESCRIPTION Browse 26 Market Data Tables and 33 Figures spread through 175 Pages and in-depth TOC on "Global Non-small Cell Lung Cancer Treatment Market , by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza) and Ramucirumab (Cyramza)), and Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027" Major market players are focused on various business strategies such as research and development, in order to enhance their market position. For instance, in March 2019, Eli Lily and Company announced the positive result for its Phase 3 RELAY study of CYRAMZA (ramucirumab), meeting primary endpoint of progression-free survival (PFS) and exhibited impressive improvement in patients that lived without their cancer spreading or growing after treatment. CYRAMZA is indicated for the treatment of Non-small cell lung cancer. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/241

© Coherent market Insights. All Rights Reserved


REPORT DESCRIPTION Key Takeaways of the Global Non-small Cell Lung Cancer Treatment Market: The global Non-small cell lung cancer treatment market is expected to exhibit a CAGR of 9.3% over the forecast period (2019-2027), owing to increasing launches of product for non-small cell lung cancer treatment Among type, adenocarcinoma segment is expected to account for a major revenue share by 2027, owing to increasing cases of lung adenocarcinoma. For instance, according to the American Cancer Society (ACS) data of October 2019, lung adenocarcinoma accounts for 40% of all lung cancers cases, globally. It is more prone in women. Furthermore, according to the same source, younger population (aged 2046), who have lung cancer are more likely to have lung adenocarcinoma than other lung cancers, globally.

Major players operating in the global Non-small cell lung cancer treatment market include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/241 © Coherent market Insights. All Rights Reserved


ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.

SERVICES INDUSTRY ANALYSIS

CUSTOMIZED RESEARCH

SYNDICATED RESEARCH

MARKET INTELLIGENCE SERVICES

CONSULT STUDIES

COUNTRY SPECIFIC STUDIES

© Coherent market Insights. All Rights Reserved


ABOUT CMI SECTOR COVERAGE

BIOTECHNOLOGY

CLINICAL DIAGNOSTIC

HEALTHCARE IT

MEDICAL DEVICES

MEDICAL IMAGING

PHARMACEUTICAL

OUR CLIENTS

 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry

 Component Providers and System Integrators

 Private and Government organization

 Distributors, Retailors and Value Added Resellers

 Outsourcing Companies

 Healthcare IT Solutions Developers

 Universities and Business Schools.

© Coherent market Insights. All Rights Reserved


KEY STATS

RESEARCH SOLUTIONS

100+

FEASIBILITY STUDIES

Insights Published Per Year

GLOBAL REPORTS

150+

Consulting Projects Till Date

COUNTRY ANALYSIS CONSULT PROJECTS

125+

Clients Worldwide Per Year

110+

SURVEY RESEARCH

EXCEL FORECAST DATABASE

CUSTOMIZED SOLUTIONS

COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS

Analysts and Contract Consultants

Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved


THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702

© Coherent market Insights. All Rights Reserved


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.